The ATTAIN-MAINTAIN trial finds that oral orforglipron helps patients maintain weight loss gained from injectable obesity drugs. This study highlights orforglipron's role in post-treatment weight control. Oral administration provides a follow-up option after injectables.
The ATTAIN-MAINTAIN trial reveals that oral orforglipron helps patients maintain weight loss achieved with injectable obesity drugs. This finding centers on transitioning from injections to an oral option for ongoing weight management.
The ATTAIN-MAINTAIN trial examined oral orforglipron specifically for weight loss maintenance. It targeted individuals who had used injectable obesity drugs beforehand. Results confirm orforglipron's ability to help sustain that weight loss.
Orforglipron stands out as an oral medication in this context. It assists patients in keeping weight off after completing injectable treatments. The trial underscores its supportive role in this phase.
Injectable obesity drugs lead to initial weight loss. Following their use, oral orforglipron steps in to help maintain those results. The ATTAIN-MAINTAIN trial documents this sequence directly.
Named ATTAIN-MAINTAIN, the trial connects oral orforglipron to sustained weight loss efforts. It addresses the period right after injectable obesity drug therapy. Orforglipron helps bridge that maintenance gap.
Peptides referenced: Orforglipron.
Related reading: ECO 2026: ATTAIN-MAINTAIN Trial Shows Orforglipron in Sustained Weight Loss, Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026, Orforglipron Maintains Weight Loss After Stopping Injections, Adults Retain Most Weight Loss After Switching to Foundayo.